The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine

Vaccine

Volumn 26, Issue 7, 2008, Pages 956-965

  Gabriel, G ^a   Garn, H ^a   Wegmann, M ^a   Renz, H ^a   Herwig, A ^a   Klenk, H D ^a   Stech, J ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Highly pathogenic influenza; Influenza life vaccine; Reverse genetics

Indexed keywords

ELASTASE; HEMAGGLUTININ; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LIVE VACCINE; PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME STRUCTURE; FEMALE; GENETIC REASSORTMENT; HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H7N7; LETHAL DOSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC; PATHOGENICITY; PRIORITY JOURNAL; REVERSE GENETIC; TECHNIQUE; VACCINATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA VACCINES; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; PANCREATIC ELASTASE; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA; VACCINES, ATTENUATED; VERO CELLS;

EID: 38649118469     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.052     Document Type: Article

References (36)

1. Olsen B., Munster V.J., Wallensten A., Waldenstrom J., Osterhaus A.D., and Fouchier R.A. Global patterns of influenza a virus in wild birds. Science 312 5772 (2006) 384-388
2. Webster R.G., Peiris M., Chen H., and Guan Y. H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 12 1 (2006) 3-8
3. Fauci A.S. Pandemic influenza threat and preparedness. Emerg Infect Dis 12 1 (2006) 73-77
4. Fouchier R.A., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A., Munster V., et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 101 5 (2004) 1356-1361
5. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., and Ypma E. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 9272 (2001) 1937-1943
6. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 1210-1215
7. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
8. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
9. de Wit E., Munster V.J., Spronken M.I., Bestebroer T.M., Baas C., Beyer W.E., et al. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 79 19 (2005) 12401-12407
10. Stieneke-Grober A., Vey M., Angliker H., Shaw E., Thomas G., Roberts C., et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 11 7 (1992) 2407-2414
11. Klenk H.D., and Garten W. Host cell proteases controlling virus pathogenicity. Trends Microbiol 2 2 (1994) 39-43
12. Orlich M., Linder D., and Rott R. Trypsin-resistant protease activation mutants of an influenza virus. J Gen Virol 76 Pt 3 (1995) 625-633
13. Scheid A., and Choppin P.W. Protease activation mutants of sendai virus. Activation of biological properties by specific proteases. Virology 69 1 (1976) 265-277
14. Stech J., Garn H., Wegmann M., Wagner R., and Klenk H.D. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 11 6 (2005) 683-689
15. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., and Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97 11 (2000) 6108-6113
16. Gabriel G., Dauber B., Wolff T., Planz O., Klenk H.D., and Stech J. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci USA 102 51 (2005) 18590-18595
17. Scheiblauer H., Kendal A.P., and Rott R. Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian species. Arch Virol 140 2 (1995) 341-348
18. Li S.Q., Orlich M., and Rott R. Generation of seal influenza virus variants pathogenic for chickens, because of hemagglutinin cleavage site changes. J Virol 64 7 (1990) 3297-3303
19. Stech J., Xiong X., Scholtissek C., and Webster R.G. Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. J Virol 73 3 (1999) 1878-1884
20. Takada A., Shimizu Y., and Kida H. Protection of mice against Aujeszky's disease virus infection by intranasal vaccination with inactivated virus. J Vet Med Sci 56 4 (1994) 633-637
21. Webster R.G., Hinshaw V.S., Bean W.J., Van Wyke K.L., Geraci J.R., St Aubin D.J., et al. Characterization of an influenza A virus from seals. Virology 113 2 (1981) 712-724
22. Mecham R.P., Broekelmann T.J., Fliszar C.J., Shapiro S.D., Welgus H.G., and Senior R.M. Elastin degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of elastolysis. J Biol Chem 272 29 (1997) 18071-18076
23. Steinhauer D.A., Wharton S.A., Skehel J.J., and Wiley D.C. Studies of the membrane fusion activities of fusion peptide mutants of influenza virus hemagglutinin. J Virol 69 11 (1995) 6643-6651
24. Klenk H.D., Rott R., Orlich M., and Blodorn J. Activation of influenza A viruses by trypsin treatment. Virology 68 2 (1975) 426-439
25. Powell T.J., Strutt T., Reome J., Hollenbaugh J.A., Roberts A.D., Woodland D.L., et al. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 178 2 (2007) 1030-1038
26. Epstein S.L., Lo C.Y., Misplon J.A., Lawson C.M., Hendrickson B.A., Max E.E., et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol 158 3 (1997) 1222-1230
27. Kreijtz J.H., Bodewes R., van Amerongen G., Kuiken T., Fouchier R.A., Osterhaus A.D., et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25 4 (2007) 612-620
28. Riberdy J.M., Flynn K.J., Stech J., Webster R.G., Altman J.D., and Doherty P.C. Protection against a lethal avian influenza A virus in a mammalian system. J Virol 73 2 (1999) 1453-1459
29. Tumpey T.M., Renshaw M., Clements J.D., and Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75 11 (2001) 5141-5150
30. Horimoto T., Takada A., Iwatsuki-Horimoto K., and Kawaoka Y. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model. Vaccine 22 17-18 (2004) 2244-2247
31. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 2 (2000) 168-175
32. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193 1 (2006) 49-53
33. Frank A.L., Taber L.H., and Wells J.M. Individuals infected with two subtypes of influenza A virus in the same season. J Infect Dis 147 1 (1983) 120-124
34. Steinhoff M.C., Fries L.F., Karron R.A., Clements M.L., and Murphy B.R. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol 31 4 (1993) 836-838
35. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5 3 (1977) 237-247
36. Perdue M.L., Garcia M., Senne D., and Fraire M. Virulence-associated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res 49 2 (1997) 173-186